CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
June 1st 2024
Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.
Gilotrif's Approval Expanded to Some Patients With Metastatic NSCLC
January 15th 2018The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.
Four-Drug Combination Improves NSCLC Outcomes
December 24th 2017A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.
Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape
December 22nd 2017Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.
Frontline Tagrisso Granted Priority Review for Lung Cancer Treatment
December 18th 2017Frontline Tagrisso (osimertinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).
Frontline Alecensa Approved for Lung Cancer Treatment
November 7th 2017Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.
Keytruda Approved for Lung Cancer
October 3rd 2015The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.
Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment
October 3rd 2015Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.